Aaron T. Mayer

Aaron T. Mayer

Auto-generated profile, based on publicly available information

Aaron T. Mayer

Enable Medicine, Menlo Park, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ISIdit Sagiv-Barfi
Idit Sagiv-Barfi
DCDebra K. Czerwinski
Debra K. Czerwinski
SLShoshana Levy
Shoshana Levy
IAIsrat S. Alam
Israt S. Alam
AMAaron T. Mayer
Aaron T. Mayer
RLRonald Levy
Ronald Levy
It has recently become apparent that the immune system can cure cancer. In some of these strategies, the antigen targets are preidentified and therapies are custom-made against these targets. In others, antibodies are used to remove the brakes of the immune system, allowing preexisting T cells to attack cancer cells. We have used another noncustomized approach called in situ vaccination. Immunoenhancing agents are injected locally into one site of tumor, thereby triggering a T cell immune response locally that then attacks cancer throughout the body. We have used a screening strategy in which the same syngeneic tumor is implanted at two separate sites in the body. One tumor is then injected with the test agents, and the resulting immune response is detected by the regression of the distant, untreated tumor. Using this assay, the combination of unmethylated CG–enriched oligodeoxynucleotide (CpG)—a Toll-like receptor 9 (TLR9) ligand—and anti-OX40 antibody provided the most impressive results. TLRs are components of the innate immune system that recognize molecular patterns on pathogens. Low doses of CpG injected into a tumor induce the expression of OX40 on CD4+ T cells in the microenvironment in mouse or human tumors. An agonistic anti-OX40 antibody can then trigger a T cell immune response, which is specific to the antigens of the injected tumor. Remarkably, this combination of a TLR ligand and an anti-OX40 antibody can cure multiple types of cancer and prevent spontaneous genetically driven cancers.

10 November 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
ZWZhenqin Wu
Zhenqin Wu
ATAlexandro E. Trevino
Alexandro E. Trevino
EWEric Wu
Eric Wu
KSKyle Swanson
Kyle Swanson
HKHonesty J. Kim
Honesty J. Kim
JZJames Y Zou
James Y Zou

1 September 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Jia WuJia Wu
Jia Wu
AMAaron T. Mayer
Aaron T. Mayer
RLRuijiang Li
Ruijiang Li

20 January 2023 in Science Advances
Verified
Journal Article
Closed access
AMAaron T. Mayer
Aaron T. Mayer
DHDerek R. Holman
Derek R. Holman
ASAnav Sood
Anav Sood
UTUtkarsh Tandon
Utkarsh Tandon
SBSalil S. Bhate
Salil S. Bhate
SRStephan Rogalla
Stephan Rogalla
Although literature suggests that resistance to TNF inhibitor (TNFi) therapy in patients with ulcerative colitis (UC) is partially linked to immune cell populations in the inflamed region, there is still substantial uncertainty underlying the relevant spatial context. Here, we used the highly multiplexed immunofluorescence imaging technology CODEX to create a publicly browsable tissue atlas of inflammation in 42 tissue regions from 29 patients with UC and 5 healthy individuals. We analyzed 52 biomarkers on 1,710,973 spatially resolved single cells to determine cell types, cell-cell contacts, and cellular neighborhoods. We observed that cellular functional states are associated with cellular neighborhoods. We further observed that a subset of inflammatory cell types and cellular neighborhoods are present in patients with UC with TNFi treatment, potentially indicating resistant niches. Last, we explored applying convolutional neural networks (CNNs) to our dataset with respect to patient clinical variables. We note concerns and offer guidelines for reporting CNN-based predictions in similar datasets.

20 September 2024 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
LLLea Lemaitre
Lea Lemaitre
NANia Adeniji
Nia Adeniji
ASAkanksha Suresh
Akanksha Suresh
RRReshma Reguram
Reshma Reguram
JZJosephine Zhang
Josephine Zhang
RDRenumathy Dhanasekaran
Renumathy Dhanasekaran

16 August 2025 in Nature Communications
Verified
Journal Article
Open access
EWEric Wu
Eric Wu
MBMatthew Bieniosek
Matthew Bieniosek
ZWZhenqin Wu
Zhenqin Wu
NTNitya Thakkar
Nitya Thakkar
GCGregory Charville
Gregory Charville
JZJames Y Zou
James Y Zou
Hematoxylin and eosin (H&E) is a common and inexpensive histopathology assay. Though widely used and information-rich, it cannot directly inform about specific molecular markers, which require additional experiments to assess. To address this gap, we present ROSIE, a deep-learning framework that computationally imputes the expression and localization of dozens of proteins from H&E images. Our model is trained on a dataset of over 1300 paired and aligned H&E and multiplex immunofluorescence (mIF) samples from over a dozen tissues and disease conditions, spanning over 16 million cells. Validation of our in silico mIF staining method on held-out H&E samples demonstrates that the predicted biomarkers are effective in identifying cell phenotypes, particularly distinguishing lymphocytes such as B cells and T cells, which are not readily discernible with H&E staining alone. Additionally, ROSIE facilitates the robust identification of stromal and epithelial microenvironments and immune cell subtypes like tumor-infiltrating lymphocytes (TILs), which are important for understanding tumor-immune interactions and can help inform treatment strategies in cancer research.